Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate a new incidence and preventive effect of menatetrenone on vertebral fracture
in patients with osteoporosis who were randomly assigned to either treatment arm receiving
daily dose of calcium supplement as a monotherapy (calcium monotherapy group) or
menatetrenone plus calcium supplement as a combination therapy (menatetrenone combo therapy
group) for 36 months, followed by a 12-month follow-up observation to examine the preventive
effect on the fracture risk.